Men with Low Testosterone See Multiple Doctors Before Being Diagnosed; Many Dissatisfied with Current Treatment Options
...
Although testosterone levels decline with age,
hypogonadism is not a natural consequence of the aging process. "Men with clinically diagnosed
hypogonadism do not need to 'tolerate' the symptoms of low ... by Bayer Schering Pharma AG.
ABOUT
hypogonadism
Hypogonadism, also known as low ...
Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show
... new long-term clinical trial data in men with
hypogonadism who were treated for 21 months with testosterone ... at Harvard Medical School . "But treating
hypogonadism can result in significant health benefits for ... Morgentaler noted: "Because men who suffer from
hypogonadism need to remain on treatment for life, it is very ...
New recommendations by scientific societies about late-onset hypogonadism
... published by Elsevier, will feature new recommendations on late-onset
hypogonadism (LOH), recently formulated by major scientific organizations. LOH is a ... symptoms and a deficiency in serum testosterone levels.
Late-onset
hypogonadism (LOH) is caused by a decline in gonadal production of androgens in males ...
FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
... to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005. About
hypogonadism Male
hypogonadism is an increasingly recognized medical condition
characterized by a reduced ...
QuatRx Announces Further Positive Phase 3 Results For Ophena(TM) (Ospemifene Tablets) in Postmenopausal Vaginal Atrophy
... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary
hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel ...
Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer
... 2004, Dr. Hamdy was a Senior Principal Scientist at Watson Pharmaceuticals where he participated in an ANDA for testosterone gel for the treatment of
hypogonadism that was approved 2005. He also participated in multiple INDs in oncology and autoimmune diseases leading to successful phase I and phase II ...
Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
... markets products to treat overactive bladder, prostate cancer and central precocious puberty and is pursuing regulatory approval of drugs to treat
hypogonadism and bladder cancer.
Mr. Holveck noted, "In addition to the very successful drug, VANTAS(R), we are particularly excited about the opportunity to ...
JCI online early table of contents: July 1, 2008
... and colleagues, at Massachusetts General Hospital, Boston, has identified mutations in the FGF8 gene in individuals with idiopathic hypogonadotropic
hypogonadism (IHH), a disease characterized by failed sexual maturation and infertility due to a deficiency in the small protein gonadotropin-releasing hormone ...
Low Serum Testosterone Levels Associated With Fall Risk in Elderly Men
... Prolonged
hypogonadism may result in erectile dysfunction, decreased libido, anemia, sarcopenia, ... level is well-known for its association with osteoporosis, the impact of
hypogonadism on overall physical functioning and fall risk has not been prospectively ...
Hypogonadism in Medical Technology
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
... in Europe and other territories.
About
hypogonadism
Male
hypogonadism is an increasingly recognized medical condition ... impair quality of life. Common effects of
hypogonadism include decreased sexual desire, erectile ...
Indevus Announces Submission of New Drug Application
... reported were comparable
to other injectable
hypogonadism treatments reported in the literature.
There were ... Schering Pharma AG, Germany in July 2005. About
hypogonadism Male
hypogonadism is an increasingly recognized medical ...
Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
... 40-69 years, it is estimated that there are about
481,000 new cases of
hypogonadism per year. Overall, approximately 2.4
million U.S. men suffer from the condition.(1)
hypogonadism results from a
deficiency in testosterone secretion that may occur ...
Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
... previously announced, are
based on a Phase III study in which men with
hypogonadism and low serum
testosterone levels prior to entering the study were treated ... Schering Pharma AG, Germany in July 2005.
About Hypogonadism
Male
hypogonadism is an increasingly recognized medical condition
characterized by a reduced ...
QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy
... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary
hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. ...
QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
... program. Fispemifene is a new selective estrogen
receptor antagonist that is in Phase 2 studies as an oral treatment for the
symptoms of secondary
hypogonadism in men. Sobetirome, a novel, selective
thyroid receptor beta agonist, is in Phase 1 studies as a potential
treatment for dyslipidemia. Asord(TM) ...
QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
... program. Fispemifene is a new selective estrogen
receptor antagonist that is in Phase 2 studies as an oral treatment for the
symptoms of secondary
hypogonadism in men. Sobetirome, a novel, selective
thyroid receptor beta agonist, is in Phase 1 as a potential treatment for
dyslipidemia. Becocalcidiol, a novel ...
Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
... program. Fispemifene is a new selective estrogen
receptor antagonist that is in Phase 2 studies as an oral treatment for the
symptoms of secondary
hypogonadism in men. Sobetirome, a novel, selective
thyroid receptor beta agonist, is in Phase 1 studies as a potential
treatment for dyslipidemia. Asord(TM) ...
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
... endocrinologists,
orthopedists and select primary care physicians. Auxilium markets Testim(R)
1%, a topical testosterone gel, for the treatment of
hypogonadism through
its approximately 190-person sales and marketing team. Auxilium has four
projects in clinical development. XIAFLEX(TM) (clostridial ...
QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
... program. Fispemifene is a new selective estrogen
receptor antagonist that is in Phase 2 studies as an oral treatment for the
symptoms of secondary
hypogonadism in men. Sobetirome, a novel, selective
thyroid receptor beta agonist, is in Phase 1 studies as a potential
treatment for dyslipidemia. Asord(TM) ...
More>>
Hypogonadism in Medical Definition
Pathology
... Adrenal insufficiency ( Addison's disease ) - Hypoaldosteronism
Gonads
Polycystic ovary syndrome - 5-alpha-reductase deficiency -
hypogonadism - Delayed puberty - Precocious puberty
Other
Autoimmune polyendocrine syndrome - Carcinoid syndrome - Laron syndrome - ...
Hypogonadism in Medical Dictionary
Hypogonadism
... Hypogonadotropic
hypogonadism Alternative Names: Gonad otropin deficiency ; Kallmann syndrome ; Secondary
hypogonadism Prevention : ... Male
hypogonadism Types of testosterone therapy Several types of ...
Hypothalamic
... from secondary ( hypothalamic or pituitary)
hypogonadism . Autonomic dysfunction may be associated with ... FSH levels may help determine if hypothalamic
hypogonadism (low FSH ) or testicular factors (high FSH ) ... alcohol or heavy metals; (2) hypogonadotropic
hypogonadism ( congenital or acquired)— idiopathic ...
Testes
... testes . This test is used to differentiate
hypogonadism ( ovary or testes ) into primary
hypogonadism (problem is with the ovary or testes ) or secondary
hypogonadism (problem is with the pituitary gland or the ...
Aplastic anemia
... Glaucoma ( Glaucoma ) Secondary Hyperparathyroidism Secondary
hypogonadism (Hypogonadotropic
hypogonadism ) ... Conditions that can decrease WBC values include chemotherapy , ...
Cryptorchidism
... a deficiency or absence of endogenous testosterone : (1) primary
hypogonadism ( congenital or acquired)—testicular failure due to ... ECG . Affected people may have abnormal genitalia ( cryptorchidism ),
hypogonadism , or delayed puberty . ^ Top ... At birth , it remains up in the ...
Testosterone
... abnormally low testosterone levels - a medical condition called male
hypogonadism . Testosterone should not be used if you are taking the supplement ... SEPA/ testosterone gel In clinical trials for the treatment of male
hypogonadism . Combining testosterone gel with the SEPA absorption enhancer allows ...
Anorexia
... fractures and can develop osteoporosis at a younger age than women without eating disorders . anorexia nervosa primary and secondary
hypogonadism turner's syndrome , seen in females with one missing X chromosome ... anorexia nervosa An eating disorder manifested primarily by a loss ...
Anorexia Nervosa
... fractures and can develop osteoporosis at a younger age than women without eating disorders . anorexia nervosa primary and secondary
hypogonadism turner's syndrome , seen in females with one missing X chromosome ... anorexia nervosa An eating disorder manifested primarily by a loss ...
Atherosclerosis
... of ED cases. Between 35 and 50 percent of men with diabetes experience ED. Additional features in some cases include hypothyroidism , male
hypogonadism , short stature and mild to moderate developmental delay and the complications of type 2 diabetes such as hyperlipidemia (high lipid s) and ...
Atrophy
... vasomotor symptoms associated with menopause , (2) treatment of vulva l and vagina l atrophy , (3) treatment of hypoestrogenism due to
hypogonadism , castration , or primary ovarian failure, ... Possible side effects associated with chronic and prolonged use of topical corticosteroids ...
More>>
Hypogonadism in Biological News
Study identifies pathway required for normal reproductive development
... of Medicine.
The current study is the latest in a series of investigations by the MGH group into the genetic basis of idiopathic hypogonadotropic
hypogonadism (IHH), a rare condition in which puberty does not take place naturally. IHH occurs when a structure in the brain called the hypothalamus fails to ...
New licensing agreement to maximize AIDS drug development
... and South Korea.
FortigelTM (testosterone gel), branded Tostrex® outside the United States, is marketed in Sweden for the treatment of male
hypogonadism also by ProStrakan. Approvals of Rectogesic and Tostrex by the other member states of the European Union are being sought through the Mutual ...
Hypogonadism in Biological Technology
Hypogonadism in Biological Definition
Infertility
... i.e. diabetes mellitus , thyroid disorders
Hypothalamic disorders, i.e. Kallmann syndrome
Hyperprolactinemia
Hypopituitarism
hypogonadism due to various causes
Psychological factors
Drugs, alcohol
Testicular factors
Genetic causes, e.g. Klinefelter syndrome
Neoplasm, ....